JAKUB TOLAR, MD
Medical Practice at Delaware St, Minneapolis, MN
License number
Minnesota 42278
Category
Medical Practice
Type
Pediatrics
License number
Minnesota 42278
Category
Medical Practice
Type
Pediatric Hematology-Oncology
Address
Address
420 Delaware St SE UNIVERSITY OF MINNESOTA PHYSICIANS, Minneapolis, MN 55455
Phone
(612) 273-2800
Personal information
See more information about JAKUB TOLAR at radaris.comName
Address
Phone
3216 44Th Ave S, Minneapolis, MN 55406
Minneapolis, MN
3216 44Th Ave S, Minneapolis, MN 55406
Organization information
See more information about JAKUB TOLAR at bizstanding.comJakub Tolar MD,PHD
420 Delaware St SE, Minneapolis, MN 55455
Industry:
Pediatric Oncologist, Pediatrician, Transplant Surgery
Phone:
(612) 626-5501 (Phone)
Jakub Tolar
Professional information
Assistant Professor At University Of Minnesota
Position:
MD, PhD at University of Minnesota, Assistant Professor at University of Minnesota
Location:
Greater Minneapolis-St. Paul Area
Industry:
Fine Art
Work:
University of Minnesota
-
MD, PhD
University of Minnesota
since Jul 1996
-
Assistant Professor
Education:
University of Minnesota-Twin Cities 1992 - 1996
PhD, molecular biology Charles University in Prague 1984 - 1990
MD, medicine
PhD, molecular biology Charles University in Prague 1984 - 1990
MD, medicine
Jakub Tolar, Minneapolis MN
Specialties:
Transplant Surgery, Pediatrics, Pediatric Hematology-Oncology, Surgical Oncology
Work:
University of Minnesota, Twin Cities
516 Delaware St SE, Minneapolis, MN 55455 University of Minnesota Medical Center, Fairview
2450 Riverside Ave, Minneapolis, MN 55454 Univ. of Minnesota Physicians
2512 S 7Th St, Minneapolis, MN 55454
516 Delaware St SE, Minneapolis, MN 55455 University of Minnesota Medical Center, Fairview
2450 Riverside Ave, Minneapolis, MN 55454 Univ. of Minnesota Physicians
2512 S 7Th St, Minneapolis, MN 55454
Education:
Charles University (1990)
Dr. Jakub Tolar, Minneapolis MN - MD (Doctor of Medicine)
Specialties:
Pediatric Hematology & Oncology
Address:
2450 Riverside Ave, Minneapolis 55454
(612) 626-6777 (Phone)
2512 S 7Th St, Minneapolis 55454
(612) 626-6777 (Phone)
Blood/Marrow Transplant Clinic
516 Delaware St SE, Minneapolis 55455
(612) 626-2663 (Phone)
(612) 626-6777 (Phone)
2512 S 7Th St, Minneapolis 55454
(612) 626-6777 (Phone)
Blood/Marrow Transplant Clinic
516 Delaware St SE, Minneapolis 55455
(612) 626-2663 (Phone)
Certifications:
Pediatric Oncology & Pediatric Hematology, 2004, Pediatrics, 2000
Awards:
Healthgrades Honor Roll
Languages:
English, Czech
Hospitals:
2450 Riverside Ave, Minneapolis 55454
2512 S 7Th St, Minneapolis 55454
Blood/Marrow Transplant Clinic
516 Delaware St SE, Minneapolis 55455
University of Minnesota Medical Center Fairview - West Bank
2312 6Th St South, Minneapolis 55454
2512 S 7Th St, Minneapolis 55454
Blood/Marrow Transplant Clinic
516 Delaware St SE, Minneapolis 55455
University of Minnesota Medical Center Fairview - West Bank
2312 6Th St South, Minneapolis 55454
Reducing Inflammation Using Cell Therapy
US Patent:
2013012, May 23, 2013
Filed:
Nov 19, 2009
Appl. No.:
13/510491
Inventors:
Steven L. Highfill - Rockville MD, US
Jakub Tolar - Minneapolis MN, US
Bruce M. Blazar - Golden Valley MN, US
Jakub Tolar - Minneapolis MN, US
Bruce M. Blazar - Golden Valley MN, US
Assignee:
Regents of the University - St Paul MN
International Classification:
A61K 35/12
US Classification:
424 937
Abstract:
The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component, including graft-versus-host disease. The invention is generally directed to reducing inflammation by administering cells that express and/or secrete prostaglandin E2 (PGE2). The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to express and/or secrete PGE2, such as PGE2 receptor agonists. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired levels of PGE2 expression and/or secretion. The invention is also generally directed to delivering cells directly to lymphohematopoietic tissue, such as spleen, lymph nodes, and bone marrow. The invention is, thus, also directed to a method for treating inflammation by administering cells directly into sites of lymphohematopoiesis, such as spleen, lymph nodes, and bone marrow. The administered cells include those that reduce the activation and/or proliferation of T-cells. Such cells may or may not express and/or secrete PGE2.
Cell Therapy For The Treatment Of Lysosomal Storage Disorders
US Patent:
8580249, Nov 12, 2013
Filed:
Apr 5, 2011
Appl. No.:
13/080109
Inventors:
Bruce Blazar - Golden Valley MN, US
Jakub Tolar - Minneapolis MN, US
Catherine M. Verfaillie - Lauven, BE
Jakub Tolar - Minneapolis MN, US
Catherine M. Verfaillie - Lauven, BE
Assignee:
Regents of the University of Minnesota - St. Paul MN
International Classification:
C12N 5/00
US Classification:
424 937, 435366
Abstract:
The present invention relates to methods for providing lysosomal enzymes to a subject by administering stem cells, preferably Multipotent Adult Progenitor Cells (MAPCs). The invention further relates to methods for treating lysosomal storage disorders by administering stem cells.
Compositions And Methods For The Treatment Of Lysosomal Storage Disorders
US Patent:
2007000, Jan 11, 2007
Filed:
Jun 2, 2006
Appl. No.:
11/446560
Inventors:
Bruce Blazar - Golden Valley MN, US
Jakub Tolar - Minneapolis MN, US
Catherine Verfaillie - St. Paul MN, US
Jakub Tolar - Minneapolis MN, US
Catherine Verfaillie - St. Paul MN, US
International Classification:
A61K 48/00
US Classification:
424093210
Abstract:
The present invention relates to methods for providing lysosomal enzymes to a subject by administering stem cells, preferably Multipotent Adult Progenitor Cells (MAPCs). The invention further relates to methods for treating lysosomal storage disorders by administering stem cells.
Use Of Nk Cell Inhibition To Facilitate Persistence Of Engrafted Mhc-I-Negative Cells
US Patent:
2008031, Dec 25, 2008
Filed:
May 5, 2005
Appl. No.:
11/919901
Inventors:
Bruce Blazar - Golden Valley MN, US
Jakub Tolar - Minneapolis MN, US
Catherine M. Verfaillie - Leuven, BE
Jakub Tolar - Minneapolis MN, US
Catherine M. Verfaillie - Leuven, BE
International Classification:
A61K 39/395, A61K 35/12, A61K 38/00, A61P 19/00, A61N 5/00
US Classification:
4241301, 424 937, 4241411, 514 2, 607 1
Abstract:
The present invention relates to the use of a means for inhibiting NK cell function to increase persistence and/or engraftment of MHC-I negative cells, such as MAPCs.